Key Takeaways
- Tirzepatide (Zepbound) produces 20.9% average body weight loss versus 14.9% for semaglutide (Wegovy) in pivotal clinical trials (SURMOUNT-1 and STEP 1)
- Semaglutide is the only GLP-1 with proven cardiovascular protection, reducing major cardiac events by 20% in the SELECT trial (NEJM, 2023)
- Both medications are once-weekly subcutaneous injections titrated over 16-20 weeks to a maintenance dose
- Tirzepatide activates two receptors (GLP-1 and GIP) while semaglutide activates only GLP-1, explaining the difference in weight loss magnitude
- Gastrointestinal side effects are similar for both drugs and typically improve after the first few weeks at each dose level
- Vitality by PACS in Alexandria, VA offers both medications as part of a physician-supervised weight loss program with metabolic monitoring
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are injectable medications that mimic the incretin hormone glucagon-like peptide-1, which your gut naturally releases after eating. These drugs amplify three biological signals: they tell the pancreas to produce insulin, they slow gastric emptying so food stays in the stomach longer, and they communicate with the hypothalamus to reduce appetite. The net effect is that patients eat less, feel satisfied sooner, and maintain lower blood glucose levels.
Two GLP-1 medications dominate the medical weight loss landscape in 2026. Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Tirzepatide is marketed as Mounjaro for diabetes and Zepbound for weight management. At Vitality by PACS in Alexandria, VA, our physician-supervised program offers both medications alongside nutritional guidance, metabolic lab monitoring, and ongoing clinical support.
How Semaglutide Works: Single-Receptor GLP-1 Agonist
Semaglutide activates the GLP-1 receptor exclusively. It is a modified version of the natural GLP-1 hormone engineered with a fatty acid side chain that binds to albumin in the blood, extending its half-life to approximately seven days. This albumin binding is what allows once-weekly dosing instead of the multiple daily injections that earlier GLP-1 drugs required.
The medication is administered as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The dose is titrated gradually over 16 to 20 weeks to minimize gastrointestinal side effects and allow the body to adapt.
Semaglutide Dosing Schedule (Wegovy)
| Week | Weekly Dose | Purpose |
|---|---|---|
| 1-4 | 0.25 mg | Initiation and GI acclimation |
| 5-8 | 0.5 mg | First escalation |
| 9-12 | 1.0 mg | Second escalation |
| 13-16 | 1.7 mg | Third escalation |
| 17+ | 2.4 mg | FDA-approved maintenance dose |
The slow titration matters. Starting at the full 2.4 mg dose would produce severe nausea in most patients. The gradual increase allows GLP-1 receptors in the gut to desensitize partially, reducing gastrointestinal side effects while maintaining appetite-suppressing efficacy in the brain.
STEP Trial Results for Semaglutide
The Semaglutide Treatment Effect in People with Obesity (STEP) program is the largest clinical trial series for any weight loss medication. These trials established semaglutide as a breakthrough therapy.
STEP 1 (New England Journal of Medicine, 2021): Researchers enrolled 1,961 adults without diabetes. Participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. Approximately 32% of participants lost 20% or more of their starting weight.
STEP 2 (Lancet, 2021): In 1,210 patients with type 2 diabetes, semaglutide produced 9.6% body weight loss versus 3.4% with placebo. Weight loss is typically lower in patients with diabetes due to insulin resistance.
STEP 3 (JAMA, 2021): When combined with intensive behavioral therapy including a low-calorie diet phase, 611 participants lost 16.0% of body weight on semaglutide.
STEP 5 (Nature Medicine, 2022): This two-year study confirmed durability. Patients on continuous semaglutide maintained 15.2% weight loss at 104 weeks, demonstrating that the medication remains effective with long-term use.
How Tirzepatide Works: Dual GIP and GLP-1 Agonist
Tirzepatide represents the next generation of incretin-based therapy. It activates two receptors simultaneously: the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is the other major incretin hormone, and activating both pathways produces stronger metabolic effects than GLP-1 alone.
The GIP pathway enhances fat oxidation in adipose tissue through mechanisms distinct from GLP-1. Research published in Cell Metabolism (2022) suggests that dual agonism improves insulin sensitivity in both the liver and muscle, promotes more favorable body composition changes, and may preferentially target visceral fat, the metabolically dangerous fat surrounding internal organs.
Tirzepatide Dosing Schedule (Zepbound)
| Week | Weekly Dose | Purpose |
|---|---|---|
| 1-4 | 2.5 mg | Initiation and GI acclimation |
| 5-8 | 5.0 mg | First escalation |
| 9-12 | 7.5 mg | Optional intermediate step |
| 13-16 | 10.0 mg | Second or third escalation |
| 17+ | 10 or 15 mg | Maintenance (dose-dependent on response) |
SURMOUNT Trial Results for Tirzepatide
The SURMOUNT trial series demonstrated that tirzepatide produces the largest weight loss of any approved anti-obesity medication.
SURMOUNT-1 (New England Journal of Medicine, 2022): Researchers enrolled 2,539 adults without diabetes. At the highest dose of 15 mg, participants lost an average of 20.9% of body weight over 72 weeks, compared to 3.1% with placebo. More than one-third of participants lost 25% or more of their body weight, a result previously achievable only through bariatric surgery.
SURMOUNT-2 (Lancet, 2023): In patients with type 2 diabetes, the 15 mg dose produced 14.7% weight loss over 72 weeks. This result in diabetic patients exceeded semaglutide's results in non-diabetic patients from STEP 1.
SURMOUNT-3 (Nature Medicine, 2023): Combined with an intensive lifestyle intervention including a 12-week low-calorie diet lead-in, participants lost 26.6% of body weight, the highest average weight loss recorded in any pharmaceutical obesity trial.
SURMOUNT-5 (2025): This head-to-head trial directly compared tirzepatide 15 mg against semaglutide 2.4 mg. Tirzepatide produced significantly greater weight loss, providing the first randomized controlled evidence of superiority in a direct comparison.
Head-to-Head Comparison: Semaglutide vs Tirzepatide
The following table summarizes the key differences between these two GLP-1 weight loss medications based on published clinical trial data.
| Factor | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual agonist |
| Average weight loss | 14.9% (STEP 1) | 20.9% (SURMOUNT-1) |
| Top-tier responders | 32% lost 20%+ of body weight | 36% lost 25%+ of body weight |
| Dosing frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Maintenance dose | 2.4 mg | 10 mg or 15 mg |
| Time to maintenance | 16-20 weeks | 16-20 weeks |
| FDA weight loss approval | Yes (Wegovy, 2021) | Yes (Zepbound, 2023) |
| Cardiovascular outcome data | SELECT trial: 20% MACE reduction | SURPASS-CVOT: ongoing |
| Pivotal trial size | 1,961 patients (STEP 1) | 2,539 patients (SURMOUNT-1) |
The SELECT Trial: Semaglutide's Cardiovascular Advantage
The SELECT trial (NEJM, 2023) was a landmark cardiovascular outcome study enrolling 17,604 patients with established cardiovascular disease. Semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo. This cardioprotective benefit was independent of weight loss, suggesting direct vascular effects.
As of 2026, this cardiovascular outcome data remains unique to semaglutide. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is still underway. For patients with established heart disease or high cardiovascular risk, this distinction is clinically significant and may favor semaglutide.
Common Side Effects of GLP-1 Medications
Both semaglutide and tirzepatide share a similar gastrointestinal side effect profile because both activate the GLP-1 receptor that slows gastric emptying.
Nausea is the most frequently reported side effect, affecting approximately 40-44% of patients in the SURMOUNT trials and 44% in the STEP trials. Nausea typically peaks during the first one to two weeks after each dose escalation and then subsides as the body adapts. Most patients describe it as mild to moderate.
Constipation or diarrhea affects 15-25% of patients and is managed with hydration, fiber adjustment, and occasionally over-the-counter remedies.
Decreased appetite is both the therapeutic mechanism and a side effect. Patients often describe a fundamental shift in their relationship with food rather than simply feeling less hungry.
Injection site reactions such as mild redness or itching occur in fewer than 5% of patients and resolve within 24 hours.
In the SURMOUNT trials, gastrointestinal side effects led to discontinuation in 4-7% of tirzepatide patients. The STEP trials reported similar discontinuation rates for semaglutide. At Vitality by PACS, our gradual titration protocols and biweekly monitoring visits help minimize side effects by adjusting dosing based on each patient's tolerance.
Which GLP-1 Medication Is Right for You?
Choosing between semaglutide and tirzepatide depends on your individual health profile, goals, and medical history. The following framework reflects current clinical evidence and the approach used at Vitality by PACS.
Tirzepatide may be the stronger choice if:
- Your primary goal is maximum weight loss and you need to lose a significant amount
- You have insulin resistance, metabolic syndrome, or prediabetes (the dual GIP/GLP-1 mechanism improves insulin sensitivity more effectively)
- You have not achieved adequate results with GLP-1 monotherapy
- You do not have established cardiovascular disease requiring proven cardioprotection
Semaglutide may be the stronger choice if:
- You have established cardiovascular disease or high cardiovascular risk (based on the SELECT trial's 20% MACE reduction)
- You want a medication with longer real-world safety data (semaglutide was approved earlier and has a larger post-marketing dataset)
- You prefer a more gradual weight loss trajectory
- Insurance coverage or cost considerations favor semaglutide
In clinical practice at our Alexandria, VA clinic, both medications produce life-changing outcomes for the majority of patients. The best choice is the one that aligns with your health profile and your provider's clinical judgment.
What to Expect on a GLP-1 Weight Loss Program
At Vitality by PACS, our medical weight loss program follows a structured protocol designed to maximize results while preserving lean muscle mass.
Initial evaluation. A comprehensive metabolic assessment includes lab work: fasting glucose, HbA1c, lipid panel, thyroid function (TSH, free T4), kidney function (BMP), and liver function (hepatic panel). These labs identify metabolic comorbidities and establish a baseline for tracking improvement.
Medication initiation. You receive your first injection at our clinic with clear titration instructions for home administration. Our nursing staff teaches proper injection technique, rotation sites, and storage requirements.
Biweekly to monthly follow-ups. Weight monitoring, body composition assessment, side effect management, and dose adjustments happen at every visit. We track waist circumference and lean mass in addition to scale weight.
Protein-forward nutrition guidance. We recommend 1.0 to 1.2 grams of protein per kilogram of ideal body weight daily to preserve muscle during caloric restriction. A 2023 study in Obesity found that higher protein intake during GLP-1 therapy reduced lean mass loss by 30-40% compared to standard dietary advice.
Complementary therapies. We offer vitamin B12 injections to support energy levels during caloric restriction and IV therapy for patients who want enhanced nutrient delivery while eating less. Reduced food intake on GLP-1 medications can decrease micronutrient absorption, making supplementation clinically important.
Frequently Asked Questions
How quickly will I lose weight on semaglutide or tirzepatide?
Most patients notice reduced appetite within the first one to two weeks of starting treatment. Measurable weight loss typically begins during weeks two through four at the starting dose. The most significant results accumulate over three to six months as the dose is titrated to the therapeutic maintenance range. In the STEP 1 trial, semaglutide patients lost approximately 1-2% of body weight per month. Find a location to start your evaluation at Vitality by PACS.
Can I take GLP-1 medications if I do not have diabetes?
Yes. Both Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) hold FDA approval specifically for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. A diabetes diagnosis is not required.
What happens when I stop taking the medication?
Clinical trials consistently show that weight regain occurs in most patients who discontinue GLP-1 therapy without sustained lifestyle changes. The STEP 4 trial found that patients who switched from semaglutide to placebo regained approximately two-thirds of their lost weight within one year. This is why our program at Vitality by PACS emphasizes building lasting nutritional and exercise habits alongside medication. Some patients taper off successfully; others benefit from long-term maintenance dosing.
Are compounded versions of semaglutide or tirzepatide safe?
The FDA has issued multiple warnings about compounded GLP-1 medications, citing concerns about potency variability, sterility, and the presence of salt forms not equivalent to the branded products. At Vitality by PACS, we use only FDA-approved brand-name medications or compounded formulations from FDA-registered 503B outsourcing facilities that meet rigorous quality and sterility standards. We discuss sourcing transparently with every patient during their initial consultation.
Medically reviewed by the Vitality by PACS clinical team. Last updated 2026-04-06.
